Details for Patent: 10,471,087
Which drugs does patent 10,471,087 protect, and when does it expire?
Patent 10,471,087 protects KYGEVVI and is included in one NDA.
This patent has sixty patent family members in twenty-seven countries.
Summary for Patent: 10,471,087
| Title: | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes |
| Abstract: | The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome. |
| Inventor(s): | Michio Hirano, Caterina Garone, Ramon Marti |
| Assignee: | Columbia University in the City of New York |
| Application Number: | US15/736,092 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 10,471,087
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,471,087
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3310362 | ⤷ Start Trial | C20265012 | Finland | ⤷ Start Trial |
| European Patent Office | 3310362 | ⤷ Start Trial | 301385 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3310362 | ⤷ Start Trial | CR 2026 00027 | Denmark | ⤷ Start Trial |
| European Patent Office | 3310362 | ⤷ Start Trial | LUC50054 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3310362 | ⤷ Start Trial | PA2026522 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3310362 | ⤷ Start Trial | 2026C/722 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
